Financhill
Sell
14

BIVI Quote, Financials, Valuation and Earnings

Last price:
$0.88
Seasonality move :
33.4%
Day range:
$0.82 - $0.88
52-week range:
$0.62 - $7.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.63x
Volume:
80K
Avg. volume:
189.9K
1-year change:
-83.31%
Market cap:
$15.1M
Revenue:
--
EPS (TTM):
-$3.46

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIVI
BioVie
-- -$0.32 -- -41.86% $5.50
ACXP
Acurx Pharmaceuticals
-- -$0.14 -- -50% $6.70
AXSM
Axsome Therapeutics
$119.8M -$1.32 61.86% -6.01% $177.12
NBY
NovaBay Pharmaceuticals
$3M -$0.24 14.03% -95.43% $0.85
PTN
Palatin Technologies
-- -$0.17 -- -67.93% --
TNXP
Tonix Pharmaceuticals Holding
$2.6M -$3.09 20.02% -99.46% $60.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIVI
BioVie
$0.82 $5.50 $15.1M -- $0.00 0% --
ACXP
Acurx Pharmaceuticals
$0.43 $6.70 $9.5M -- $0.00 0% --
AXSM
Axsome Therapeutics
$112.29 $177.12 $5.5B -- $0.00 0% 13.95x
NBY
NovaBay Pharmaceuticals
$0.58 $0.85 $3.4M -- $0.00 0% 0.16x
PTN
Palatin Technologies
$0.20 -- $5.2M -- $0.00 0% --
TNXP
Tonix Pharmaceuticals Holding
$18.02 $60.00 $116M -- $0.00 0% 2.26x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIVI
BioVie
-- -0.718 -- --
ACXP
Acurx Pharmaceuticals
-- 2.025 -- --
AXSM
Axsome Therapeutics
76.02% 1.593 4.39% 1.99x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
PTN
Palatin Technologies
-- 1.358 -- --
TNXP
Tonix Pharmaceuticals Holding
5.09% -9.057 5.18% 5.84x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIVI
BioVie
-- -$7.3M -- -- -- -$8.6M
ACXP
Acurx Pharmaceuticals
-- -$2.8M -- -- -- -$2.3M
AXSM
Axsome Therapeutics
$108.3M -$61.6M -96.73% -244.32% -61.14% -$26.2M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTN
Palatin Technologies
-- -- -- -- -- --
TNXP
Tonix Pharmaceuticals Holding
$1.4M -$21.6M -127.14% -138.47% -834.78% -$14.6M

BioVie vs. Competitors

  • Which has Higher Returns BIVI or ACXP?

    Acurx Pharmaceuticals has a net margin of -- compared to BioVie's net margin of --. BioVie's return on equity of -- beat Acurx Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.46 --
    ACXP
    Acurx Pharmaceuticals
    -- -$0.16 --
  • What do Analysts Say About BIVI or ACXP?

    BioVie has a consensus price target of $5.50, signalling upside risk potential of 572.62%. On the other hand Acurx Pharmaceuticals has an analysts' consensus of $6.70 which suggests that it could grow by 1457.56%. Given that Acurx Pharmaceuticals has higher upside potential than BioVie, analysts believe Acurx Pharmaceuticals is more attractive than BioVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    2 0 0
    ACXP
    Acurx Pharmaceuticals
    1 0 0
  • Is BIVI or ACXP More Risky?

    BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison Acurx Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BIVI or ACXP?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Acurx Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Acurx Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or ACXP?

    BioVie quarterly revenues are --, which are smaller than Acurx Pharmaceuticals quarterly revenues of --. BioVie's net income of -$7.1M is lower than Acurx Pharmaceuticals's net income of -$2.8M. Notably, BioVie's price-to-earnings ratio is -- while Acurx Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus -- for Acurx Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$7.1M
    ACXP
    Acurx Pharmaceuticals
    -- -- -- -$2.8M
  • Which has Higher Returns BIVI or AXSM?

    Axsome Therapeutics has a net margin of -- compared to BioVie's net margin of -63.08%. BioVie's return on equity of -- beat Axsome Therapeutics's return on equity of -244.32%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.46 --
    AXSM
    Axsome Therapeutics
    91.15% -$1.54 $237.7M
  • What do Analysts Say About BIVI or AXSM?

    BioVie has a consensus price target of $5.50, signalling upside risk potential of 572.62%. On the other hand Axsome Therapeutics has an analysts' consensus of $177.12 which suggests that it could grow by 57.73%. Given that BioVie has higher upside potential than Axsome Therapeutics, analysts believe BioVie is more attractive than Axsome Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    2 0 0
    AXSM
    Axsome Therapeutics
    13 0 0
  • Is BIVI or AXSM More Risky?

    BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.356%.

  • Which is a Better Dividend Stock BIVI or AXSM?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or AXSM?

    BioVie quarterly revenues are --, which are smaller than Axsome Therapeutics quarterly revenues of $118.8M. BioVie's net income of -$7.1M is higher than Axsome Therapeutics's net income of -$74.9M. Notably, BioVie's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 13.95x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$7.1M
    AXSM
    Axsome Therapeutics
    13.95x -- $118.8M -$74.9M
  • Which has Higher Returns BIVI or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to BioVie's net margin of -49.65%. BioVie's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.46 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About BIVI or NBY?

    BioVie has a consensus price target of $5.50, signalling upside risk potential of 572.62%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.27%. Given that BioVie has higher upside potential than NovaBay Pharmaceuticals, analysts believe BioVie is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    2 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is BIVI or NBY More Risky?

    BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock BIVI or NBY?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or NBY?

    BioVie quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. BioVie's net income of -$7.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, BioVie's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$7.1M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M -$1.2M
  • Which has Higher Returns BIVI or PTN?

    Palatin Technologies has a net margin of -- compared to BioVie's net margin of --. BioVie's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.46 --
    PTN
    Palatin Technologies
    -- -- --
  • What do Analysts Say About BIVI or PTN?

    BioVie has a consensus price target of $5.50, signalling upside risk potential of 572.62%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3400%. Given that Palatin Technologies has higher upside potential than BioVie, analysts believe Palatin Technologies is more attractive than BioVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    2 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is BIVI or PTN More Risky?

    BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

  • Which is a Better Dividend Stock BIVI or PTN?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or PTN?

    BioVie quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. BioVie's net income of -$7.1M is higher than Palatin Technologies's net income of --. Notably, BioVie's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$7.1M
    PTN
    Palatin Technologies
    -- -- -- --
  • Which has Higher Returns BIVI or TNXP?

    Tonix Pharmaceuticals Holding has a net margin of -- compared to BioVie's net margin of -856.24%. BioVie's return on equity of -- beat Tonix Pharmaceuticals Holding's return on equity of -138.47%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.46 --
    TNXP
    Tonix Pharmaceuticals Holding
    54.18% -$9.77 $147M
  • What do Analysts Say About BIVI or TNXP?

    BioVie has a consensus price target of $5.50, signalling upside risk potential of 572.62%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $60.00 which suggests that it could grow by 232.96%. Given that BioVie has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe BioVie is more attractive than Tonix Pharmaceuticals Holding.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    2 0 0
    TNXP
    Tonix Pharmaceuticals Holding
    1 0 0
  • Is BIVI or TNXP More Risky?

    BioVie has a beta of 1.180, which suggesting that the stock is 18.039% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 1.626, suggesting its more volatile than the S&P 500 by 62.649%.

  • Which is a Better Dividend Stock BIVI or TNXP?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or TNXP?

    BioVie quarterly revenues are --, which are smaller than Tonix Pharmaceuticals Holding quarterly revenues of $2.6M. BioVie's net income of -$7.1M is higher than Tonix Pharmaceuticals Holding's net income of -$22.1M. Notably, BioVie's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 2.26x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$7.1M
    TNXP
    Tonix Pharmaceuticals Holding
    2.26x -- $2.6M -$22.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Is Okta Stock Finally Gaining Investor Confidence?
Is Okta Stock Finally Gaining Investor Confidence?

Given how digital transformation has proliferated, cyberattacks have also been…

Stock Ideas

Buy
61
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 37x

Alerts

Sell
50
RGC alert for May 1

Regencell Bioscience Holdings [RGC] is up 10.83% over the past day.

Sell
38
WGS alert for May 1

GeneDx Holdings [WGS] is down 0.67% over the past day.

Sell
43
VICR alert for May 1

Vicor [VICR] is up 0.48% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock